Method for treating the cases of allergic diseases

FIELD: medicine.

SUBSTANCE: method involves introducing autologic mesenchyma trunk cells as a single intravenous drop dose or in the amount of 1 mln cells per 1 kg of patient body weight.

EFFECT: provided stable clinical remission.

The invention relates to medicine, more specifically to Allergology and immunology, and may find application in the treatment of allergic diseases of various origins.

Allergic diseases at the present time, according to who, suffering from not less than 30% of the population. It is associated with adverse environmental, technological and other factors. Total Allergy not only in itself causes huge financial losses, but also inevitably leads to aggravation of other diseases, and also worsens their prognosis.

The treatment of allergic diseases currently present a serious problem. Modern medicine has a significant Arsenal of drugs and treatment regimens for skin allergies (Duhatschek, Dlling. Secrets of dermatology // TRANS. from English. - M.; SPb.: Publisher BINOM Nevsky dialect, 1999. - P.57-156, S-418, S-468), as well as drugs for systemic exposure (Reference therapist / edited Fionaluv. - M.: Medicine, 1979, 656 S.; Handbook of General practitioner /Neprochnov, Vaasana etc. // ed Nuraliev. - M.: EKSMO-Press, 2001. - T.1 - c.306-322). However, more than half of the patients the effect of the application of any scheme of medical treatment is incomplete and short-lived.

Closest to the proposed method is a method lectually diseases through the application of a combination of mixed drugs (Handbook of General practitioner. // Edited Nuraliev. - M.: EKSMO-Press. - 2001. - T.1.- C.306-322).

The method consists in carrying out specific and nonspecific desensitization.

Specific desensitization is subcutaneous injection of identified allergens in low titers after chemical modification. Disadvantages of the method are the duration of treatment and a large number of injections. In the introduction of the allergen can be painful infiltrates, possible systemic reactions (urticaria, asthma, exacerbation of chronic infections). In severe somatic diseases, pregnancy, rheumatism, tuberculosis, malignant tumors, gastric ulcer and other diseases such treatment is contraindicated because it causes aggravation of the disease. More than half of the patients suffering from allergies, search specific antigen is unsuccessful, and some antigens do not exist in the modified dosage forms.

Nonspecific desensitization with severe allergies is carried out in two stages. At the first stage for the relief of acute manifestations of Allergy are forcing diuresis (intravenous drip 1500-2000 ml of physiological solution, at the end of infusion 40 mg of latexa intravenously or intramuscularly); stimulate peristalsis (25% solution MAGN what Ziya inside). In the second stage, which lasts until clinical effect (7-12 days), prescribed drugs calcium (10% solution of calcium chloride - 1 times a day intravenously); chelators (polifan a tablespoon 3 times a day), antihistamines (suprastin 1 tablet 3 times a day or Telfast 1 tablet 1 time per day). In severe cases, the treatment is supplemented by the introduction of prednisolone 90 mg per day. The disadvantages of this treatment are: incomplete and short-lived effect, the need for long courses of treatment, a gradual reduction in efficiency and the consequent need to increase doses, negative effects on many organs and systems, eg, severe chronic diseases, pregnancy, malignancy, glucocorticoid hormones (prednisolone) is contraindicated.

The technical result of the present invention is to reduce the manifestations of allergic diseases and improve patients ' quality of life through the use of autologous mesenchymal stem cells (AMSC).

This result is achieved by the fact that in the treatment of allergies according to the invention once the patient intravenously injected isolated from biopsies his bone marrow was ASK in the amount of 1 million cells per 1 kg of body weight of the patient.

AMSC in recent years started is to use when treating patients with cardiac pathology to improve tissue regeneration (Handbook of Cardiovascular Cell Transplantation.- Ed. N.M.Kipstidze et al.- 2004. - 425 p.).

ASK is the fraction of highly purified autologous stem cells. To obtain AMSC you want to take 20-35 ml bone marrow (the procedure is performed under local short-term intravenous anesthesia and lasts 10-15 min). In a further fraction of AMSC stands out from the bone marrow, thepirouette and grown in a special medium. After 10-12 days from the start of culturing, the number of AMSC reaches 80-100 million, which is ten times higher than the content in the bone marrow. Back introduction AMSC is safe (own cells, there is no risk of allergic reactions), the number of input cells allows to receive the expressed clinical effect.

To use ASK in the treatment RMP us prompted the observation of patients admitted to the clinic in cnerry with a diagnosis of Coronary heart disease. Angina and rest of the 3-rd functional class. Ateroskleroticeski and postinfarction cardiosclerosis (myocardial infarction 1994, 1995, 2004). Status after coronary artery bypass grafting (1996). Circulatory insufficiency II.

In addition to cardiac pathology in the patient there was a strong food paillere, which began about 12 years ago. Allergies were called different, often unknown food, and there was a drain in the papular SIP is, occupying the skin of the chest, back and forearms. The patient is constantly took suprastin, periodically - prednisolone.

The goal of entering the patient was koronaroangiografii (CAT) to assess the condition of the vessels of the heart and treatment. When performing coronary angiography was planned the introduction of intracoronary ASK to improve cardiac muscle performance. For this one month prior to this admission, the patient was taken 30 ml of bone marrow and cultured 100 million ASK.

However, the CAG was associated with a high risk of increased allergic reactions in response to the injection of a contrast agent. It was therefore decided to limit intravenous drip was AMSC dose of 76 million (1 million cells per 1 kg of patient's body weight), which was completed in April 2004

Totally unexpected effect from the introduction of OMSK was the reduction of skin allergies, which began on the 5th day after injection. Two weeks later, skin rash completely disappeared, and the patient was able to refuse the acceptance of anti-allergic drugs, which he used for many years in continuous mode.

In June 2004, the patient underwent a CAT that he had no adverse reactions and complications.

Allergies the patient has to date not available, it eats a variety of food, including the KJV is rebleed products and juices, previously inevitably caused a pronounced skin rash. Such persistent anti-allergic effect of AMSC allowed us to apply further transplantation ASK patients with severe allergies.

The essence of the method is illustrated by examples.

Example 1. Patient M., 59 years old, medical history, No. 814, received 17. 05. 2004 in the Department of new technologies in radiotherapy clinic cnerry health Ministry. Sick for 20 years, suffering from food allergies, which is expressed by a rash on the face, chest and back, accompanied by itching. Upon admission of the patient to the clinic he observed significant the Allergy symptoms in the form of papular rash all over the body, itching, runny nose, worsened his General condition and substantially disrupts sleep.

To relieve allergic reactions was proposed biotransplant his bone marrow.

For this 25.05.2004 the patient was made fence 30 ml of own bone marrow and grown culture was ASK and 08.06.2004 78 million AMSC (1 million cells per kg of body weight) were introduced to the patient intravenously in 50 ml of culture suspension. Introduction the patient underwent without reactions and complications. 12 million was AMSC were placed in a cryo-Depositary for possible future use.

7 days after the introduction of AMSC allergic skin manifestations in a patient stopped, which allowed to hold him further Leche is the concomitant diseases of the cardiovascular system. Despite taking quite a large number of drugs, the patient was not observed any allergic manifestations, whereas previously he almost couldn't drink any tablets without additional intake of antihistamines.

Up to the present time the condition and the patient's health is satisfactory. The patient offered when he has an allergic reaction at any time of the year, immediately contact the Institute for the relief of its introduction ASK stored in a cryo-Depositary institution.

Example 2. Patient K., aged 63, case history No. 517, received 16.02.2004 in the Department of new technologies in radiotherapy clinic cnerry MH RF, where the survey diagnosed perekhodnocletocny urinary bladder carcinoma T2N0M0. Among opportunistic diseases - ischemic heart disease, myocardial infarction in 1999, circulatory failure, 2nd degree, and hay fever. Sick for 15 years suffered from severe allergies (“hay fever”) with the annual spring exacerbations. Since allergic reactions (March - April) the patient within 2-3 months took large doses of antihistamines (suprastin, tavegil) and glucocorticoid (prednisone, dexamethasone) drugs. On the background of the treatment of Allergy (skin rash, shortness of breath, runny nose, ISU is Remy skin) decreased, but never fully disappeared.

In connection with severe concomitant diseases (severe cardiac pathology, and also strong allergic history) were contraindications for surgical and chemotherapeutic treatment. Therefore, the only treatment for this patient was to undergo radiation therapy after removal of allergies by introducing him to ASK. The patient was offered biotransplant own bone marrow.

To do this, prior to treatment the patient was made fence 25 ml of own bone marrow and grown culture was ASK. 19.03.2004 72 million was ASK (1 million cells per kg of body weight) were introduced to the patient intravenously in 50 ml of culture suspension. Introduction the patient underwent without reactions and complications. 12 million was AMSC were placed in a cryo-Depositary for possible future use.

With 26.02.2004, started a course of radiation therapy, in standard mode, up to a total focal dose of 68 Gy.

A course of radiation treatment was completed in mid-April, when the patient annually for symptoms of hay fever. This year for the first time in 15 years on the background of the treatment of allergies was not. To date, the patient's condition remains stable.

To date, the proposed method, the treatment of three patients with a positive effect. Received the initial effect remain with them until the present time.

The method of treatment of allergic diseases through the use of medical means, characterized in that as a remedy using autologous mesenchymal stem cells are administered once intravenously in the amount of 1 million cells per 1 kg of body weight of the patient.